A possible pitfall in acyclovir prophylaxis for recurrent herpetic keratitis?

Journal of Infectious Diseases

Volumn 208, Issue 9, 2013, Pages 1353-1355

  James, Scott H ^a   Prichard, Mark N ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Acyclovir; Herpes simplex virus; Keratitis; resistance

Indexed keywords

ACICLOVIR; CIDOFOVIR; FOSCARNET; GANCICLOVIR; PENCICLOVIR; THYMIDINE KINASE; TRIFLURIDINE; VALACICLOVIR;

BLEPHARITIS; CLINICAL DECISION MAKING; CONJUNCTIVITIS; CORNEA ULCER; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; EYE INFECTION; HERPES SIMPLEX; HERPES SIMPLEX KERATITIS; HUMAN; INFECTION PREVENTION; INFECTION RISK; MUTATIONAL ANALYSIS; NEPHROTOXICITY; NERVE FIBER TRANSPORT; NONHUMAN; OUTCOME ASSESSMENT; PRIMARY INFECTION; PRIORITY JOURNAL; RECURRENT INFECTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; TRIGEMINAL NERVE; TRIGEMINUS GANGLION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN;

ACYCLOVIR; HERPES SIMPLEX VIRUS; KERATITIS; RESISTANCE;

ACYCLOVIR; ANIMALS; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; HERPES SIMPLEX; HUMANS; KERATITIS, HERPETIC; MALE;

EID: 84885414324     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit379     Document Type: Review

References (22)

1. Perng GC, Jones C. Towards an understanding of the herpes simplex virus type 1 latency-reactivation cycle. Interdiscip Perspect Infect Dis 2010; 2010:262415
2. Holland EJ, Schwartz GS. Classification of herpes simplex virus keratitis. Cornea 1999; 18:144-54
3. Al-Dujaili LJ, Clerkin PP, Clement C, et al. Ocular herpes simplex virus: How are latency, reactivation, recurrent disease and therapy interrelated? FutureMicrobiol 2011; 6:877-907
4. Lairson DR, Begley CE, Reynolds TF, Wilhelmus KR. Prevention of herpes simplex virus eye disease: A cost-effectiveness analysis. Arch Ophthalmol 2003; 121:108-12
5. Elion GB. Mechanism of action and selectivity of acyclovir. Am J Med 1982; 73:7-13
6. Andrei G, Snoeck R, De Clercq E. Susceptibilities of several drug-resistant herpes simplex virus type 1 strains to alternative antiviral compounds. Antimicrob Agents Chemother 1995; 39:1632-5
7. Safrin S, Crumpacker C, Chatis P, et al. A controlled trialcomparingfoscarnetwithvidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl JMed 1991; 325:551-5
8. Sacks SL, Griffiths PD, Corey L, et al. HSV shedding. Antiviral Res 2004; 63 (Suppl 1): S19-26
9. Falcon MG. Herpes simplex virus infections of the eye and their management with acyclovir. J Antimicrob Chemother 1983; 12 (Suppl B):39-43
10. Acyclovir for the prevention of recurrent herpes simplex virus eye disease. Herpetic Eye Disease Study Group. N Engl J Med 1998; 339:300-6
11. Predictors of recurrent herpes simplex virus keratitis. Herpetic Eye Disease Study Group. Cornea 2001; 20:123-8
12. Stranska R, Schuurman R, Nienhuis E, et al. Survey of acyclovir-resistant herpes simplex virus in the Netherlands: Prevalence and characterization. J Clin Virol 2005; 32:7-18
13. Kriesel JD, Spruance SL, Prichard M, Parker JNKern ER. Recurrent antiviral-resistant genital herpes in an immunocompetent patient. J Infect Dis 2005; 192:156-61
14. Bacon TH, Levin MJ, Leary JJ, Sarisky RT, Sutton D. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev 2003; 16:114-28
15. Fife KH, Crumpacker CS, Mertz GJ, Hill EL, Boone GS. Recurrence and resistance patterns of herpes simplex virus following cessation of > or = 6 years of chronic suppression with acyclovir. Acyclovir Study Group. J Infect Dis 1994; 169:1338-41
16. van Velzen M, van de Vijver DA, van Loenen FB, Osterhaus AD, Remeijer L, Verjans GM. Acyclovir Prophylaxis Predisposes to Antiviral Resistant Recurrent Herpetic Keratitis. J Infect Dis 2013; 208:1359-65
17. Duan R, van Dun JM, Remeijer L, et al. Prevalence of herpes simplex virus type 1 glycoprotein G (gG) and gI genotypes in patients with herpetic keratitis. Br J Ophthalmol 2008; 92:1195-200
18. Duan R, de Vries RD, van Dun JM, et al. Acyclovir susceptibility and genetic characteristics of sequential herpes simplex virus type 1 corneal isolates from patients with recurrent herpetic keratitis. J Infect Dis 2009; 200:1402-14
19. Hazlett LD, Hendricks RL. Reviews for immune privilege in the year 2010: Immune privilege and infection. Ocul Immunol Inflamm 2010; 18:237-43
20. Kennedy DP, Clement C, Arceneaux RL, Bhattacharjee PS, Huq TS, Hill JM. Ocular herpes simplex virus type 1: Is the cornea a reservoir for viral latency or a fast pit stop? Cornea 2011; 30:251-9
21. Prichard MN, Kern ER, Hartline CB, Lanier ERQuenelle DC. CMX001 potentiates the efficacy of acyclovir in herpes simplex virus infections. Antimicrob Agents Chemother 2011; 55:4728-34
22. Biswas S, Jennens L, Field HJ. The helicase primase inhibitor, BAY 57-1293 shows potent therapeutic antiviral activity superior to famciclovir in BALB/c mice infected with herpes simplex virus type 1. Antiviral Res 2007; 75:30-5